Skip to content
  • (312) 598-2610
  • info@ipfdalaw.com
  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
Untitled design (7)
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
中文

Day: June 24, 2025

Your Rights If FDA Agreed To Your Proposed Q1/Q2 ANDA Formulation But Sends A Refuse to Receive (RTR) Instead?

The pharmaceutical industry is complex and expensive. Companies and investors deserve certainty. Imagine asking an agency what to do, the agency tells you to do X, you invest time/effort/resources into doing X, and when you file the drug application on X, the agency says “oops, it’s not-X”. The applicant is ambushed and doesn’t know why […]

Patents
Hatch-Waxman Litigation
Trade Secrets
Antitrust/Unfair Competition
FDA Counseling
Branded/Generic/ 505(b)(2)
Life Cycles
Contracts Licensing
Freedom to Operate

Quick Contact

Address

  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
  • (312) 598-2610
  • info@ipfdalaw.com

Ⓒ 2021 - IPFDA law All Rights Are Reserved